XENE - Xenon Pharmaceuticals Inc Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Global Market Current Price & Safety Score Price: 36.34 USD StockBonds Safety Grade: D Altman Z-Score (Bankruptcy Risk): 37.13 StockBond Score: -0.22 Company Description Xenon Pharmaceuticals Inc is a clinicalstage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders The company operates primarily from its headquarters in Burnaby Canada Its robust clinical pipeline showcases several promising candidates XEN496 an activator of Kv7 potassium channels is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy Another Kv7 potassium channel activator XEN1101 is progressing through Phase II trials targeting epilepsy and a range of other neurological conditions The portfolio also includes NBI921352 a selective inhibitor of the Nav16 sodium channel which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy alongside investigations for adult focal epilepsy and other potential indications Furthermore XEN007 a central nervous systemacting calcium channel modulator is also in Phase II development Beyond its internal development Xenon Pharmaceuticals has established strategic collaborations This includes a licensing and development agreement with Neurocrine Biosciences Inc focused on epilepsy treatments and a partnership with Flexion Therapeutics Inc to advance PCRX301 also known as XEN402 a Nav17 inhibitor for postoperative pain management Established in 1996 the company continues its mission to address significant unmet medical needs in neurology